Virtual Library
Start Your Search
Z. Qiu
Author of
-
+
P3.14 - Radiotherapy (ID 730)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.14-016 - Research About Different Administration Mode of Endostar for Combining with Concurrent Chemoradiotherapy in Local Advanced NSCLC (ID 10158)
09:30 - 09:30 | Author(s): Z. Qiu
- Abstract
Background:
Radiotherapy is carried out five days in a week. Endostar is a target drug, its adminstration is d1-14 in three weeks. We changed endostar adminstration mode as the same of radiotherpy, five days in a week. Now we evaluate the efficacy and safety of different administration dose of endostar combined with concurrent chemoradiotherapy in ad vanced non-small cell lung cancer(NSCLC).
Method:
From September 2010 to December 2015，40 patients with local advanced NSCLC were recruited. All the patients received radiotherapy with 60Gy and two circles chemotherapy with docetaxel 75mg/m[2] d1 and cisplatin 75mg/m[2] d1～3，combined with two different administration dose of endostar(75mg/m[2] d1-14 in three weeks for two cycles and 75mg/m[2] d1-5 in one week for six cycles concurrent with radiotherapy. Tumor response were evaluated with RECIST1.1 criteria. Acute toxicities were evaluated with NCICTC3.0 and RTOG criteria.
Result:
In group one，2 patients achieved complete response，10 partial response，3 stable disease，5 progressive disease. Overall response rate was 60%. The 1-year progressive-free-survive rate was 40%. The 1-，2-year survival rates were 70% and 25%. The median overall survive is 19.9 month. In group two，overall response rate was 75%. The 1-year progressive-free-survive rate was 50%. The 1-，2-year survival rates were 80% and 45%. The median overall survive is 22.7 month. In group 2 there had a good survival and patient compliance, but there were no significant difference between two groups (P>0.05).
Conclusion:
Endostar combined with concurrent chemoradiotherapy is useful and well-tolerance. Administration mode of endostar combining with chemoradiotherapy, which is five day in a week for six weeks, had a better result and patient compliance.
